•  

News - Page 30 of 36 - TIAP

OtoSim featured in Health Research & Innovation, receives B Corp Designation (video)

OtoSim Inc., a MaRS Innovation spin-of company, was featured along with MaRS Innovation in the Autumn 2012 edition of Health Research & Innovation magazine. The article by Tim Wilson is titled: "The Business of Health Innovation: How Startups Find Funding." Here's an excerpt: "The doctors [Vito Forte and Paolo Campisi] designed OtoSim and did a clinical validation on the prototype, says Andrew Sinclair, OtoSim's CEO. "They then disclosed the invention to SickKids, who passed it to MaRS Innovation, which is a partnership of the ... Read more

Gen Magazine features Dr. Aaron Wheeler’s research in microfluidics

GEN Magazine (Genetic Engineering and Biotechnology News) featured the microfluidics research of Dr. Aaron Wheeler on November 15, 2012. Wheeler, Canada Research Chair of Bioanalytical Chemistry and an associate professor at the University of Toronto, has made an invention disclosure to MaRS Innovation; Kapplex is the start-up company created to commercialize his research. (more…) Read more

OICR and MaRS Innovation announce funding to develop Cellax™, a nanotechnology-based cancer drug

TORONTO, ON (November 13, 2012) — The Ontario Institute for Cancer Research (OICR) and MaRS Innovation (MI) today announced $1.5 million in funding from OICR over three years to further develop Cellax™, a nanoparticle drug that could offer an alternative to chemotherapy with fewer side effects. “Cellax is promising because it provides a more targeted strategy for treating tumours, killing tumour cells while minimizing the effect on healthy tissue,” said Dr. Rima Al-awar, director, OICR’s Medicinal Chemistry Platform. “OICR is proud to ... Read more

Dr. Raphael Hofstein’s guest column posted on Biotechnology Focus

Biotechnology Focus, a compendium of the Canadian life sciences industry, has published a guest column by MaRS Innovation President & CEO, Raphael Hofstein. The article examines how to build a strong biotechnology cluster from an academic base in the midst of a global recession. Here's an excerpt: Gone are the days of large-scale, well-funded, in-house departments with resources to liberally support academic and start-up collaborations. Financial pressures and the economic downturn have made it clear that the go-it-alone model is no longer sustainable, and ... Read more

Stem Cell Therapeutics, UHN and MaRS Innovation Announce Novel, Clinical-Stage, Cancer Stem Cell Program Agreement

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS), a life sciences company developing stem cell-related technologies, today announced the signing of an agreement with University Health Network (UHN), through its commercialization agent MaRS Innovation (MI), both of Toronto. The agreement provides Stem Cell Therapeutics ("SCT") with an option to an exclusive world-wide license to an innovative cancer stem cell program. This agreement produced a license for a UHN technology on April 17, 2013. (more…) Read more

Yonge Street Media covers Bedside Clinical Systems’ launch

Yonge Street Media, a weekly online magazine that covers talent, innovation, diversity and quality of life stories in the Toronto region, covered Bedside Clinical Systems' (BCS) launch in their Innovation section on Wednesday, November 7, 2012. BCS is a MaRS Innovation spin-off company created to commercialize decision-support research emerging from The Hospital for Sick Children (SickKids). (more…) Read more

Bedside Clinical Systems aims to bring better healthcare to children

Each year, 5,000 children in North American hospitals experience code-blue incidents; a code blue is an event where patients require immediate resuscitation. One quarter of these incidents result in death, and Bedside Clinical Systems (BCS) seeks to drastically improve this statistic by launching its flagship solution, Bedside Paediatric Early Warning System (BedsidePEWS™). “BedsidePEWS™ is a unique software solution that helps hospital clinicians to identify deteriorating children early, giving them a window of opportunity to intervene and potentially avoid code blue incidents,” says Rajesh ... Read more

Shotlst CEO featured in Globe article on future of tech in education

Matt Ratto, assistant professor in the University of Toronto's Faculty of Information and co-inventor and CEO of Shotlst, a UTEST company, was featured in the Globe and Mail on October 22 in an article by Nick Rockel on how emerging technology will change the education experience. Here's an excerpt: Asked what the technological tools in university classrooms will look and feel like by 2020, Matt Ratto admits he’s no futurist. But the assistant professor at the University of Toronto’s Faculty of Information is ... Read more

We’ve refreshed our website: Beta version now live

Welcome to the beta version of the MaRS Innovation website. We have refreshed the site's design to make better use of its existing functionality while  showcasing our projects. The new design includes these additions and changes: (more…) Read more

Baxter and MaRS Innovation Form Strategic Partnership

Partnership to invest up to $1M in promising Canadian healthcare discoveries TORONTO, Ontario, October 4, 2012—Baxter International Inc. and MaRS Innovation, a Centre of Excellence for Commercialization and Research, have entered into a strategic partnership to commercialize early-stage technologies that present innovative methods in therapeutics and drug discovery technologies. Information about Baxter and MaRS Innovation's partnership is also available in French. The partnership’s shared vision for delivering novel, transformative therapeutic technologies will benefit Canadians and others around the world. Baxter and MaRS Innovation will ... Read more
Page 30 of 36« First...1020...2829303132...Last »